SURGE Therapeutics Stock / BioTech & PharmaFounded: 2016

SURGE, The Intraoperative Immunotherapy Company™, envisions a world where all cancer patients undergoing tumor resection receive intraoperative immunotherapy to prevent recurrence and metastasis. Aiming to change the standard of care, SURGE focuses on transforming the deployment of cancer immunotherapy to improve survival outcomes dramatically. Their approach is dedicated to delivering focused immunotherapy treatments, redefining how, when, and where they are administered to cancer patients.

Register To Buy and Sell Shares

For more details on financing and valuation for SURGE Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access SURGE Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like SURGE Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Michael Goldberg Ph.D
Founder, Chief Executive Officer & President
Charles Carignan MD
Chief Experience Officer

Board Members

Oliver Keown MD
Intuitive Ventures

Frequently Asked Questions About SURGE Therapeutics’ Stock

Can you buy SURGE Therapeutics’ stock?
SURGE Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy SURGE Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell SURGE Therapeutics’ stock?
Yes, you can sell stock of a private company like SURGE Therapeutics. Forge can help you sell your SURGE Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is SURGE Therapeutics’ stock price?
SURGE Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access SURGE Therapeutics’ private market stock price with Forge Data.
What is SURGE Therapeutics’ stock ticker symbol?
SURGE Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

This Startup Just Raised $32 Million To Keep Cancers From Recurring After Surgery
On Wednesday, the company announced it has raised a $32 million series B round. The deal brings its total venture investments to $60 million. The company plans to use the new investment to continue development of its immunotherapy and to advance clinical trials for it.
Updated on: Apr 20, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.